Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine

Brenda L. Banwell, Kinji Ohno, Joern P. Sieb, Andrew G Engel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Rapsyn is essential for clustering the acetylcholine receptor at the postsynaptic membrane of the neuromuscular junction. Direct sequencing of RAPSN in two children with congenital myasthenic syndromes with no mutation in any of the AChR subunits identified two heterozygous recessive mutations in each: a previously characterized N88K mutation in both, and a second frameshifting mutation in Patient (Pt) 1 and a nonsense mutation in Pt 2. An intercostal muscle biopsy in Pt 1 revealed decreased AChRs per endplate and decreased amplitude of the miniature endplate potential, predicted consequences of rapsyn deficiency. Clinically, both children manifested with hypomotility in utero, fatigable ocular and limb weakness since birth, decreased strength during viral illness, decremental response on electromyography, and absence of AChR antibodies. Pt 1, however, had a more severe clinical course with recurrent episodes of respiratory failure, contractures, and craniofacial malformations. In both patients, treatment with pyridostigmine was of some benefit, but the addition of 3,4-diaminopyridine led to significant clinical improvement. Thus, rapsyn deficiency predicting similar consequences at the cellular level can result in phenotypes with marked differences in severity of symptoms, risk of respiratory failure, and presence of contractures and craniofacial malformations.

Original languageEnglish (US)
Pages (from-to)202-207
Number of pages6
JournalNeuromuscular Disorders
Volume14
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Congenital Myasthenic Syndromes
Mutation
Contracture
Respiratory Insufficiency
Pyridostigmine Bromide
Intercostal Muscles
Neuromuscular Junction
Nonsense Codon
Electromyography
Cholinergic Receptors
Cluster Analysis
Extremities
3,4-diaminopyridine
Parturition
Phenotype
Biopsy
Membranes
Antibodies
peripheral membrane protein 43K

Keywords

  • 3,4-Diaminopyridine
  • Congenital myasthenic syndrome
  • Human rapsyn deficiency
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine. / Banwell, Brenda L.; Ohno, Kinji; Sieb, Joern P.; Engel, Andrew G.

In: Neuromuscular Disorders, Vol. 14, No. 3, 03.2004, p. 202-207.

Research output: Contribution to journalArticle

@article{bae3a4f3f0d34a9caffe4e0214d22034,
title = "Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine",
abstract = "Rapsyn is essential for clustering the acetylcholine receptor at the postsynaptic membrane of the neuromuscular junction. Direct sequencing of RAPSN in two children with congenital myasthenic syndromes with no mutation in any of the AChR subunits identified two heterozygous recessive mutations in each: a previously characterized N88K mutation in both, and a second frameshifting mutation in Patient (Pt) 1 and a nonsense mutation in Pt 2. An intercostal muscle biopsy in Pt 1 revealed decreased AChRs per endplate and decreased amplitude of the miniature endplate potential, predicted consequences of rapsyn deficiency. Clinically, both children manifested with hypomotility in utero, fatigable ocular and limb weakness since birth, decreased strength during viral illness, decremental response on electromyography, and absence of AChR antibodies. Pt 1, however, had a more severe clinical course with recurrent episodes of respiratory failure, contractures, and craniofacial malformations. In both patients, treatment with pyridostigmine was of some benefit, but the addition of 3,4-diaminopyridine led to significant clinical improvement. Thus, rapsyn deficiency predicting similar consequences at the cellular level can result in phenotypes with marked differences in severity of symptoms, risk of respiratory failure, and presence of contractures and craniofacial malformations.",
keywords = "3,4-Diaminopyridine, Congenital myasthenic syndrome, Human rapsyn deficiency, Therapy",
author = "Banwell, {Brenda L.} and Kinji Ohno and Sieb, {Joern P.} and Engel, {Andrew G}",
year = "2004",
month = "3",
doi = "10.1016/j.nmd.2003.11.004",
language = "English (US)",
volume = "14",
pages = "202--207",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine

AU - Banwell, Brenda L.

AU - Ohno, Kinji

AU - Sieb, Joern P.

AU - Engel, Andrew G

PY - 2004/3

Y1 - 2004/3

N2 - Rapsyn is essential for clustering the acetylcholine receptor at the postsynaptic membrane of the neuromuscular junction. Direct sequencing of RAPSN in two children with congenital myasthenic syndromes with no mutation in any of the AChR subunits identified two heterozygous recessive mutations in each: a previously characterized N88K mutation in both, and a second frameshifting mutation in Patient (Pt) 1 and a nonsense mutation in Pt 2. An intercostal muscle biopsy in Pt 1 revealed decreased AChRs per endplate and decreased amplitude of the miniature endplate potential, predicted consequences of rapsyn deficiency. Clinically, both children manifested with hypomotility in utero, fatigable ocular and limb weakness since birth, decreased strength during viral illness, decremental response on electromyography, and absence of AChR antibodies. Pt 1, however, had a more severe clinical course with recurrent episodes of respiratory failure, contractures, and craniofacial malformations. In both patients, treatment with pyridostigmine was of some benefit, but the addition of 3,4-diaminopyridine led to significant clinical improvement. Thus, rapsyn deficiency predicting similar consequences at the cellular level can result in phenotypes with marked differences in severity of symptoms, risk of respiratory failure, and presence of contractures and craniofacial malformations.

AB - Rapsyn is essential for clustering the acetylcholine receptor at the postsynaptic membrane of the neuromuscular junction. Direct sequencing of RAPSN in two children with congenital myasthenic syndromes with no mutation in any of the AChR subunits identified two heterozygous recessive mutations in each: a previously characterized N88K mutation in both, and a second frameshifting mutation in Patient (Pt) 1 and a nonsense mutation in Pt 2. An intercostal muscle biopsy in Pt 1 revealed decreased AChRs per endplate and decreased amplitude of the miniature endplate potential, predicted consequences of rapsyn deficiency. Clinically, both children manifested with hypomotility in utero, fatigable ocular and limb weakness since birth, decreased strength during viral illness, decremental response on electromyography, and absence of AChR antibodies. Pt 1, however, had a more severe clinical course with recurrent episodes of respiratory failure, contractures, and craniofacial malformations. In both patients, treatment with pyridostigmine was of some benefit, but the addition of 3,4-diaminopyridine led to significant clinical improvement. Thus, rapsyn deficiency predicting similar consequences at the cellular level can result in phenotypes with marked differences in severity of symptoms, risk of respiratory failure, and presence of contractures and craniofacial malformations.

KW - 3,4-Diaminopyridine

KW - Congenital myasthenic syndrome

KW - Human rapsyn deficiency

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=1242316360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242316360&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2003.11.004

DO - 10.1016/j.nmd.2003.11.004

M3 - Article

VL - 14

SP - 202

EP - 207

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 3

ER -